download
FREE KOL List
    • KOL
    • KOLs Community
    • Antiphospholipid
    • Antiphospholipid Syndrome
    • Jean Charles Piette
    • Jean Charles Piette

      Jean Charles Piette

      Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; Reference Center for Complex Congénital Cardiac Malformations - M3C, ...

       

       

      KOL Resume for Jean Charles Piette

      Year
      2022

      Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; Reference Center for Complex Congénital Cardiac Malformations - M3C, Necker-Enfants Malades Hospital, Université from Paris, Paris, France; Obstetrics and maternal-fetal unit / APHP Hôpital Necker-Enfant Malades, Université from Paris, Paris, France; Department of Internal Medicine, CHU Nantes, France; Rare Autoimmune and Systemic Diseases Competence Center, Reims, France; Pitié-Salpêtrière Hospital, Reference Center for Rare Autoimmune and Systemic Diseases, Paris, France; Timone Children's Hospital, Unité of Pediatric Resuscitation, Marseille, France; Tenon Hospital, Paris, France; CHU Fort de France, Martinique, France; Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Systemic Autoimmune Diseases in the North and North-West of France (CeRAINO) , U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France; Cardiopédiatrics, University Hospital of Nantes, France; Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; University Paris Descartes- Sorbonne Paris Cité, Paris, France; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. Address for correspondence: Nathalie Costedoat-Chalumeau, Hôpital Cochin, 75014, Paris, France. Fax number: +33158413246. Phone number: +33687508123

      Department of internal medicine, Pitié Salpêtrière Hospital, AP-HP, 83 Boulevard de l'Hôpital, 75013 Paris, France.

      2021

      AP-HP, Pitié-Salpétrière University Hospital, Internal Medicine and Clinical Immunology Department, Centre de référence maladies auto-immunes et systémiques rares de l’Ile de France, Paris, France

      2020

      Department of Internal Medicine and Clinical Immunology, Centre de Référence Maladies Auto-Immunes et Systémiques Rares de l’île de France, Pitié-Salpêtrière University Hospital, APHP

      AP-HP, Hôpital Pitié-Salpêtrière, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne 2, 47-83 Boulevard de l’Hôpital, 75651, Paris Cedex 13, France

      2019

      A.C. Desbois, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; L. Biard, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; D. Sène, MD, PhD, AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine; I. Brocheriou, MD, PhD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; P. Rouvier, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pathology; B. Lioger, MD, PhD, Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine; L. Musset, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratory of Immunology; S. Candon, MD, PhD, Hôpital Necker, Laboratory of Immunology; T. Zenone, MD, Centre Hospitalier de Valence, Department of Internal Medicine; M. Resche-Rigon, MD, PhD, Département de Biostatistiques, Hôpital Saint-Louis; J.C. Piette, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; N. Benameur, MD, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Pharmacy; P. Cacoub, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology; D. Saadoun, MD, PhD, DHU Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology. Dr. Cacoub and Dr. Saadoun are co-senior authors.

      From the Départements Hospitalo-Universitaires (DHU) Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Department of Pathology, Laboratory of Immunology, and Pharmacy Department; Département de Biostatistiques, Hôpital Saint-Louis; AP-HP, Groupe Hospitalier Lariboisière, Department of Internal Medicine, Paris; Hôpital Bretonneau, Centre Hospitalier de Tours, Department of Internal Medicine, Tours; Hôpital Necker, Laboratory of Immunology, Paris; Centre Hospitalier de Valence, Department of Internal Medicine, Valence, France.

      2018

      Service de Médecine Interne, Hôpital Pitié Salpetrière, Université Paris, APHP, Paris, France.

      Internal Medicine Department, AP‐HP, Pitié‐Salpêtrière Hospital, Université Pierre et Marie Curie, Paris, France

      2017

      2 Département Hospitalo-Unviversitaire I2B, UPMC Univ Paris 06, Paris, France.

      Service de médecine interne, Hôpital Pitié Salpetrière, APHP, Université Paris 6, Paris, France

      2016

      UPMC, Université Paris 6 and AP-HP, Hôpital Pitié-Salpêtrière, service de médecine interne, Paris, France.

      Assistance publique–Hôpitaux de Paris, université Pierre-et-Marie-Curie, hôpital Pitié-Salpêtrière, centre de référence national pour le lupus systémique et le syndrome des antiphospholipides, département de médecine interne et d’immunologie clinique, 47-83, boulevard de l’Hôpital, 75651 Paris cedex 13, France

      G. Thomas, MD, APHP, Service de Médecine Interne, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Service de Réanimation, Hôpital Européen; F. Cohen Aubart, MD, PhD, APHP, Service de Médecine Interne, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides, Hôpital de la Pitié-Salpêtrière; L. Chiche, MD, PhD, Service de Médecine Interne, Hôpital Européen; J. Haroche, MD, PhD, APHP, Service de Médecine Interne, Institut E3M, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides, Hôpital de la Pitié-Salpêtrière; M. Hié, MD, APHP, Service de Médecine Interne, Institut E3M, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides, Hôpital de la Pitié-Salpêtrière; B. Hervier, MD, PhD, APHP, Service de Médecine Interne, Institut E3M, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides, Hôpital de la Pitié-Salpêtrière; N. Costedoat-Chalumeau, MD, PhD, APHP, Service de Médecine Interne, Centre de référence maladies auto-immunes et systémiques rares, and Université Paris Descartes-Sorbonne Paris Cité; K. Mazodier, MD, APHM, Service de Médecine interne, Hôpital de la Conception; M. Ebbo, MD, APHM, Service de Médecine interne, Hôpital de la Timone; P. Cluzel, MD, PhD, APHP, Service de Radiologie, Pitié-Salpêtrière; N. Cordel, MD, Unité de Dermatologie-Médecine Interne, EA4546, CHU Pointe à Pitre; D. Ribes, MD, Département de Néphrologie et Transplantation, CHU de Toulouse; J. Chastre, MD, PhD, APHP, Service de Réanimation, INSERM, UMRS-1166, ICAN; N. Schleinitz, MD, PhD, APHM, Service de Médecine interne, Hôpital de la Timone; V. Veit, MD, APHM, Service de Médecine interne, Hôpital de la Timone; J.C. Piette, MD, Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides; J.R. Harlé, MD, PhD, APHM, Service de Médecine interne, Hôpital de la Timone; A. Combes, MD, PhD, APHP, Service de Réanimation, INSERM, UMRS-1166, ICAN, and Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI; Z. Amoura, MD, MSc, APHP, Service de Médecine Interne, Hôpital de la Pitié-Salpêtrière and Sorbonnes Universités, UPMC Université Paris VI, and Centre National de Référence pour les Maladies systémiques rares, Lupus et Syndrome des Anticorps antiphospholipides, Hôpital de la Pitié-Salpêtrière.

      2015

      Université Pierre et Marie Curie, AP‐HP, Hôpital Pitié‐Salpêtrière, and Centre de Référence pour le Lupus Systémique et le Syndrome des Antiphospholipides Paris France

      2014

      Department of Internal medicine and Clinical Immunology, Centre de référence des maladies autoimmunes et systémiques rares, AP-HP, Hôpital Pitié-Salpétrière, Paris, France

      2013

      Assistance Publique-Hôpitaux de Paris (AP-HP) (N.M., Z.A., J.-C.P., D.B., D.S., N.C.-C.), Hôpital Pitié-Salpêtrière, Centre de référence national pour le Lupus Systémique et le syndrome des Antiphospholipides, service de médecine interne, 75651 Paris Cedex 13, France

      2012

      Department of Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, 47 boulevard de l'Hôpital, 75013 Paris, France

      2011

      Service de médecine interne, université Pierre-et-Marie-Curie, Paris-6, hôpital Pitié-Salpêtrière, Assistance publique–Hôpitaux de Paris, 47-83, boulevard de l’Hôpital, 75013 Paris, France

      Professor of Medicine, Adjunct Professor of Biochemistry and Molecular Biology UMDNJ, New Jersey Medical School, Newark, NJ, USA

      2010

      Pitié‐Salpêtrière Hospital, Paris, France

      Department of Internal Medicine, Assistance Publique–Hopitaux de Paris, Groupe Hospitalier Pitié-Salpétrière, Paris;

       

       

      Jean Charles Piette: Influence Statistics

      Sample of concepts for which Jean Charles Piette is among the top experts in the world.
      Concept World rank
      sixoccasions #1
      cctg7 #1
      conventional immunosuppressants interferon #1
      aged polychondritis #1
      gynecological tolerability #1
      french patients aa #1
      nonadherence treatment #1
      dm hematological malignancy #1
      vein ovt #1
      97 procedures data #1
      table pph #1
      wegeners granulomatosis factors #1
      3 cytokines rp #1
      même entité #1
      fatigue arthralgia #1
      baisse visuelle sévère #1
      ifnalpha2a discontinuation #1
      episode hellp #1
      aps events patients #1
      new tools detection #1
      malignancies immunosuppressants #1
      presence abeta2gpi #1
      longest form #1
      primary aps ttp #1
      12 30 aps #1
      sle beneficial effects #1
      spinal cord sarcoidosis #1
      followup sle #1
      woman creatininaemia #1
      hydroxychloroquine 94 #1
      polychondrite #1
      relapsing prognosis #1
      highdose ifnα organs #1
      cd4ccr2 cells #1
      nucleosome plasma levels #1
      humans polychondritis #1
      wg pcp #1
      splenic aseptic abscesses #1
      control live birth #1
      complications apl #1
      apsn sle #1
      iufd 29 years #1
      longterm outcome apls #1
      anti‐ssa #1
      aosd rhs #1
      chapter 57 antimalarials #1
      systemic vasculitis cases #1
      672 months #1
      planned oit ivfet #1
      encephalopathy cerebrospinal fluid #1

       

      Prominent publications by Jean Charles Piette

      KOL-Index: 14370

      OBJECTIVE: Hepatitis C virus (HCV)-related vasculitis may involve multiple organs, including the skin, kidneys, and nervous system, and may be life-threatening. Although HCV is increasingly recognized as a cause of systemic vasculitis, limited data are available regarding the optimal treatment of this potentially serious condition. Therefore, we retrospectively analyzed the response to treatment in patients with chronic hepatitis C complicated by systemic vasculitis who had received ...

      Known for Systemic Vasculitis | Ribavirin Treatment | Antiviral Therapy | Hcv Rna | Followup Patients
      KOL-Index: 14342

      BACKGROUND/AIMS: Mixed cryoglobulinemia is frequently associated with liver diseases. The respective role of hepatitis C virus (HCV) and liver damage in the pathogenesis of cryoglobulinemia is investigated in this study.

      METHODS: The prevalence of cryoglobulinemia in 226 consecutive patients with chronic liver diseases (hepatitis C, 127; hepatitis B, 40; other diseases, 59) was studied, and the epidemiological, biological, histological, and virological features in these three groups were ...

      Known for Liver Diseases | Patients Cryoglobulinemia | Hcv Proteins | Cryoglobulins Cirrhosis | Hepatitis Virus
      KOL-Index: 14181

      BACKGROUND: Mixed cryoglobulinemia (MC) is frequently associated with clinical and biological evidence of liver disease and has recently been reported in cases of hepatitis C virus (HCV) infection. The aim of this study was to assess prospectively in a large series of MC patients: (1) the prevalence of HCV markers (anti-HCV antibodies and HCV RNA in serum and cryoprecipitate); (2) the main clinical, biologic and liver histologic features in patients with or without HCV ...

      Known for Mixed Cryoglobulinemia | Patients Hcv | Essential Mc | Hepatitis Antibodies | Rna Serum
      KOL-Index: 13554

      Several studies have shown a relationship between pretreatment hepatitis C virus (HCV) viral load and the response to interferon (IFN) therapy, creating a need for quantitative HCV-RNA assays. Here, we compared three commercial methods: nucleic acid sequence-based amplification NASBA (Organon), branched DNA 2.0 (bDNA) (Chiron), and Monitor (Roche), with reverse-transcription polymerase chain reaction (RT-PCR) as the reference. We assessed sensitivity and reproducibility on a ...

      Known for Branched Dna | Hcv Rna | Comparative Evaluation | Diagnostic Reproducibility | Chronic Hepatitis
      KOL-Index: 12856

      OBJECTIVE: To analyze the clinical and immunologic manifestations of antiphospholipid syndrome (APS) in a large cohort of patients and to define patterns of disease expression.

      METHODS: The clinical and serologic features of APS (Sapporo preliminary criteria) in 1,000 patients from 13 European countries were analyzed using a computerized database.

      RESULTS: The cohort consisted of 820 female patients (82.0%) and 180 male patients (18.0%) with a mean +/- SD age of 42 +/- 14 years at study ...

      Known for Antiphospholipid Syndrome | Disease Expression | Livedo Reticularis | Patients Aps | Higher Frequency
      KOL-Index: 12597

      OBJECTIVE: To assess the prevalence and clinical significance of small-vessel vasculitis (SVV) surrounding an uninflamed temporal artery (TA) in patients diagnosed as having giant cell (temporal) arteritis (GCA) and/or polymyalgia rheumatica (PMR).

      METHODS: Patients with GCA and/or PMR (n = 490) were included in this multicenter prospective study. Slides of TA biopsy specimens were reviewed by 2 pathologists who were blinded with regard to clinical information. SVV was defined as ...

      Known for Polymyalgia Rheumatica | Uninflamed Temporal Artery | Patients Svv | Gca Pmr | Diagnostic Criterion
      KOL-Index: 12552

      OBJECTIVE: To study the frequency and disease specificity of antinucleosome antibody reactivity in diverse connective tissue diseases (CTD), and to determine factors, such as antibody subclass, that may influence the pathogenicity of these antibodies in relation to disease activity.

      METHODS: IgG and IgM antinucleosome activities on nucleosome core particles from 496 patients with 13 different CTD and 100 patients with hepatitis C were measured by enzyme-linked immunosorbent assay ...

      Known for Tissue Disease | Antinucleosome Autoantibodies | Systemic Lupus Erythematosus | Active Sle | Immunoglobulin Lupus
      KOL-Index: 12396

      OBJECTIVE: Recent studies have shown that in vitro endothelial cells are activated by antiphospholipid antibodies and may support leukocyte adhesion. We studied levels of soluble intercellular adhesion molecule 1 (sICAM-1, sCD54), soluble vascular cell adhesion molecule 1 (sVCAM-1, sCD106), and soluble E-selectin (soluble endothelial leukocyte adhesion molecule 1 [sELAM-1, sCD62E]) in sera from patients with primary antiphospholipid syndrome (primary APS), and compared them with those ...

      Known for Lupus Erythematosus | Primary Aps | Cell Adhesion | Patients Thrombosis | Soluble Vascular
      KOL-Index: 12143

      The objective of this study was to determine the HLA class II associations of the anticardiolipin (aCL) and anti-beta2GPI (abeta2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). A cohort of 577 European SLE patients was enrolled. aCL and abeta2GPI were measured by ELISA methods. Molecular typing of HLA-DRB1, DRB3, DRB4, DRB5, DQA1 and DQB1 loci was performed by the polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP) ...

      Known for European Patients | Lupus Erythematosus | Large Series | Hla Class | Positive Association
      KOL-Index: 12094

      OBJECTIVE: To examine the predictive value of clinical examination, laboratory tests and Doppler ultrasound examination in systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) pregnancies.

      METHODS: A prospective study of 116 pregnancies followed in a single tertiary referral centre. Outcomes analysed were fetal/neonatal death and adverse pregnancy outcome. Univariate analysis was performed for: (i) medical and obstetric history; (ii) medical and obstetric clinical ...

      Known for Systemic Lupus Erythematosus | Antiphospholipid Syndrome | Pregnancy Outcome | Doppler Ultrasonography | Uterine Artery
      KOL-Index: 12083

      OBJECTIVE: To study the characteristics of the haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome in the antiphospholipid syndrome (APS) and its influence on the subsequent pregnancies.

      METHODS: This was a retrospective analysis of 16 episodes of HELLP complicating APS in 15 women.

      RESULTS: HELLP was complete in 10 cases and partial in six. It occurred during the second trimester in seven cases (the earliest at 18 weeks' gestation), the third trimester in seven cases, and ...

      Known for Hellp Syndrome | Cases Women | Fetal Death | Eclampsia Pregnancy | Live Birth
      KOL-Index: 12041

      AIM: Severe uveitis is potentially associated with visual impairment or blindness in young patients. Therapeutic strategies remain controversial. The efficacy of interferon alpha-2a (IFN-alpha2a) in severe uveitis, refractory to steroids and conventional immunosuppressive agents, was evaluated.

      PATIENTS AND METHODS: Patients were included after a major relapse of uveitis following corticosteroids and immunosuppressants. IFN-alpha2a (3 million units three times a week) was administered ...

      Known for Interferon Alpha | Behçets Disease | Severe Uveitis | Patients Behçet | Retinal Vasculitis
      KOL-Index: 12004

      OBJECTIVE: Infiltrating lymphocytes have been demonstrated to play an important role in the tissue injury that occurs in systemic lupus erythematosus (SLE). Inflammatory chemokines control lymphocyte traffic through their interaction with T cell chemokine receptors. In this study we assessed the expression of chemokine receptors on T cell subsets of patients with active or inactive SLE.

      METHODS: Forty-four SLE patients (40 women and 4 men) were included in the study. The patients were ...

      Known for Sle Patients | Cxcr3 Receptors | Lupus Erythematosus | Cd4 Cells | Ccr2 Expression

      Key People For Antiphospholipid Syndrome

      Top KOLs in the world
      #1
      Munther A Khamashta
      antiphospholipid syndrome systemic lupus erythematosus anticardiolipin antibodies
      #2
      Ronald H W M Derksen
      antiphospholipid antibodies systemic lupus erythematosus lupus anticoagulant
      #3
      Ricard Cervera
      antiphospholipid syndrome systemic lupus erythematosus sle patients
      #4
      Yehuda Shoenfeld
      autoimmune diseases antiphospholipid syndrome systemic lupus erythematosus
      #5
      Michael D Lockshin
      systemic lupus erythematosus antiphospholipid syndrome fetal death
      #6
      Takao KOIKE
      rheumatoid arthritis antiphospholipid syndrome anticardiolipin antibodies

      Jean Charles Piette:Expert Impact

      Concepts for whichJean Charles Piettehas direct influence:Antiphospholipid syndrome,  Systemic lupus erythematosus,  Lupus erythematosus,  Systemic lupus,  Antiphospholipid antibodies,  Mixed cryoglobulinemia,  Dermatologic manifestations,  Arterial lesions.

      Jean Charles Piette:KOL impact

      Concepts related to the work of other authors for whichfor which Jean Charles Piette has influence:Antiphospholipid syndrome,  Systemic lupus erythematosus,  Lupus nephritis,  Autoimmune diseases,  Sle patients,  Chronic hepatitis,  Rheumatoid arthritis.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; Reference Center for Complex Congénital Cardiac Malformations - M3C, Necker-Enfants Malades Hospital, Université from Paris, Paris, France; Obstetri

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.